Atomwise
AI-powered structure-based drug discovery.
About Atomwise
Pioneer in AI for molecule screening — has predicted activity for hundreds of millions of small molecules.
Pitch deck breakdown
How Atomwise would pitch themselves.
Target customer
Customers in the Atomwise space — typically operators or teams running into the problem this product solves.
Problem they solve
Pioneer in AI for molecule screening — has predicted activity for hundreds of millions of small molecules. The category has historically been served by tools that miss the modern workflow this product is built around.
Key differentiator
Atomwise differentiates on ai-powered structure-based drug discovery. Backed by BV + B Capital, $174M+ raised — the company has resources + validation to compound this thesis. Founded by Abraham Heifets + team.
Go-to-market strategy
Growth-stage GTM — multi-channel revenue motion (direct enterprise sales, channel partnerships, marketplace listings). Vertical specialisation + verticalised AE teams targeting enterprise + mid-market.
Company facts
- Category
- Other
- Funding stage
- Series B
- Total raised
- $174M+
- Founded
- 2012
- Team size
- 51-200
- HQ
- San Francisco
- Country
- United States
- Website
- atomwise.com
Founders of Atomwise
- Abraham Heifets
- Izhar Wallach
Investors backing Atomwise
- BV
- B Capital
- DCVC
Frequently asked questions
What does Atomwise do?
Pioneer in AI for molecule screening — has predicted activity for hundreds of millions of small molecules.
Where is Atomwise based?
Atomwise is based in San Francisco, United States.
When was Atomwise founded?
Atomwise was founded in 2012.
How much has Atomwise raised?
Atomwise has raised $174M+ in their Series B round.
Who founded Atomwise?
Atomwise was founded by Abraham Heifets, Izhar Wallach.
Who has invested in Atomwise?
Atomwise is backed by BV, B Capital, DCVC.